Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial.
Methodist Hospital, Houston, Texas 77030.
C M
CM
Pratt
D C
DC
Brater
F E
FE
Harrell
P R
PR
Kowey
C V
CV
Leier
D T
DT
Lowenthal
F
F
Messerli
M
M
Packer
E L
EL
Pritchett
J N
JN
Ruskin
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D005424:Flecainide / Q000009:adverse effects; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D000889:Anti-Arrhythmia Agents; D005424:Flecainide